Search research articles
Contact Us
Filters
Showing results (21-30 of 117) with videos related to
Page
of 12
Sort By:
Urologic Oncology
|
September 9, 2020
Pushing the limits of metastasis-directed treatment in metastatic renal cell carcinoma in the era of targeted therapy
Serge Holz, Lorenzo Tosco, Murat Akand, et al.
Clinical Genitourinary Cancer
|
March 30, 2023
Pseudoprogression and Mixed Responses in Metastatic Renal Cell Carcinoma Patients Treated With Nivolumab: A Retrospective Analysis
Lorenz Haaker, Marcella Baldewijns, Liesbeth De Wever, et al.
European Urology Open Science
|
May 11, 2022
Molecular Heterogeneity Between Paired Primary and Metastatic Lesions from Clear Cell Renal Cell Carcinoma
Eduard Roussel, Lisa Kinget, Annelies Verbiest, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 30, 2022
Incidence of Cardiovascular Events in Patients Treated With Immune Checkpoint Inhibitors
Dorien Laenens, Yuling Yu, Béatrice Santens, et al.
Dento Maxillo Facial Radiology
|
May 20, 2026
Lamina dura thickening in patients on antiresorptive therapy as a radiographic risk indicator of MRONJ: a retrospective longitudinal cohort study
Sonya Radi, Samy El Bachaoui, Ilya Tsiklin, et al.
European Journal of Clinical Pharmacology
|
June 1, 2020
Impact of concomitant acid suppressive therapy on pazopanib efficacy and dose reductions in patients with metastatic renal cell carcinoma
Greet Van De Sijpe, Benoit Beuselinck, Tine Van Nieuwenhuyse, et al.
Current Oncology (Toronto, Ont.)
|
August 27, 2021
Multitumor Case Series of Germline <i>BRCA1</i>, <i>BRCA2</i> and <i>CHEK2</i>-Mutated Patients Responding Favorably on Immune Checkpoint Inhibitors
Lisa Kinget, Oliver Bechter, Kevin Punie, et al.
Clinical Genitourinary Cancer
|
May 28, 2014
Sarcomatoid dedifferentiation in metastatic clear cell renal cell carcinoma and outcome on treatment with anti-vascular endothelial growth factor receptor tyrosine kinase inhibitors: a retrospective analysis
Benoit Beuselinck, Evelyne Lerut, Pascal Wolter, et al.
Acta Oncologica (Stockholm, Sweden)
|
October 24, 2015
Prognostic factors in second-line targeted therapy for metastatic clear-cell renal cell carcinoma after progression on an anti-vascular endothelial growth factor receptor tyrosine kinase inhibitor
Anne Sacré, Philippe Barthélémy, Clement Korenbaum, et al.
Urologic Oncology
|
November 13, 2022
Predicting short- and long-term renal function following partial and radical nephrectomy
Eduard Roussel, Annouschka Laenen, Bimal Bhindi, et al.
Page
of 12
Search research articles
Search
Showing results (21-30 of 117) with videos related to
Sort By:
Page
of 12
Urologic Oncology
|
September 9, 2020
Pushing the limits of metastasis-directed treatment in metastatic renal cell carcinoma in the era of targeted therapy
Serge Holz, Lorenzo Tosco, Murat Akand, et al.
Clinical Genitourinary Cancer
|
March 30, 2023
Pseudoprogression and Mixed Responses in Metastatic Renal Cell Carcinoma Patients Treated With Nivolumab: A Retrospective Analysis
Lorenz Haaker, Marcella Baldewijns, Liesbeth De Wever, et al.
European Urology Open Science
|
May 11, 2022
Molecular Heterogeneity Between Paired Primary and Metastatic Lesions from Clear Cell Renal Cell Carcinoma
Eduard Roussel, Lisa Kinget, Annelies Verbiest, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 30, 2022
Incidence of Cardiovascular Events in Patients Treated With Immune Checkpoint Inhibitors
Dorien Laenens, Yuling Yu, Béatrice Santens, et al.
Dento Maxillo Facial Radiology
|
May 20, 2026
Lamina dura thickening in patients on antiresorptive therapy as a radiographic risk indicator of MRONJ: a retrospective longitudinal cohort study
Sonya Radi, Samy El Bachaoui, Ilya Tsiklin, et al.
European Journal of Clinical Pharmacology
|
June 1, 2020
Impact of concomitant acid suppressive therapy on pazopanib efficacy and dose reductions in patients with metastatic renal cell carcinoma
Greet Van De Sijpe, Benoit Beuselinck, Tine Van Nieuwenhuyse, et al.
Current Oncology (Toronto, Ont.)
|
August 27, 2021
Multitumor Case Series of Germline <i>BRCA1</i>, <i>BRCA2</i> and <i>CHEK2</i>-Mutated Patients Responding Favorably on Immune Checkpoint Inhibitors
Lisa Kinget, Oliver Bechter, Kevin Punie, et al.
Clinical Genitourinary Cancer
|
May 28, 2014
Sarcomatoid dedifferentiation in metastatic clear cell renal cell carcinoma and outcome on treatment with anti-vascular endothelial growth factor receptor tyrosine kinase inhibitors: a retrospective analysis
Benoit Beuselinck, Evelyne Lerut, Pascal Wolter, et al.
Acta Oncologica (Stockholm, Sweden)
|
October 24, 2015
Prognostic factors in second-line targeted therapy for metastatic clear-cell renal cell carcinoma after progression on an anti-vascular endothelial growth factor receptor tyrosine kinase inhibitor
Anne Sacré, Philippe Barthélémy, Clement Korenbaum, et al.
Urologic Oncology
|
November 13, 2022
Predicting short- and long-term renal function following partial and radical nephrectomy
Eduard Roussel, Annouschka Laenen, Bimal Bhindi, et al.
Page
of 12